Abstract:BACKGROUND:With the development of genetic mutations and targeted drugs, accurate therapy of lung adenocarcinoma attracts much more attention, and more research is focued on epidermal growth factor receptor (EGFR). It is unclear whether the result of EGFR mutation and pathology type is consistent with different specimens. In our study, by comparing the relationship between EGFR mutations and pathological classification of lung adenocarcinoma in surgical resection of specimen and biopsy specimen, to discuss the relationship between EGFR mutations and pathological classification of and the influence of specimen type on EGFR gene detection. METHODS:A total of 163 cases of surgical resection of sample of lung adenocarcinoma (pulmonary resection and pulmonary lobectomy) and 173 cases of biopsy specimen [mucosa biopsy, needle biopsy of lung, and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)] were performed by gene sequencing method and amplification refractory mutation system (ARMS) and the majority of the type was confirmed (lepidic, acinar, papillary, micropapillary, solid) according to the classification of lung adenocarcinoma in 2015 World Health Organization (WHO). The statistics was used in surgical and biopsy sample respectively. RESULTS:The gene mutation of EGFR in surgical and biopsy sample of lung adenocarcinoma was 62.58% (102/163) and 65.9% (114/173) respectively, and no significant difference was found (P>0.05). The mutation of EGFR in female was predominant both of the two groups (P<0.05). The mutation rate of EGFR over the age of 60 was significantly lower than that below 60 in surgical specimen, while it was not related to age in biopsy sample. The constituent ratio of pathology type was different in the two groups (χ2=8.04, P<0.05). Among 102 cases of lung adenocarcinoma in surgical specimen, the acinar took up the highest proportion (54.9%), followed by the lepidic (23.53%) and the papillary (17.65%). The solid adenocarcinoma accounted for the minimal percentage (3.9%). The mutation of 19 and 21 exon alone was most common. The mutation rate of 21 exon in the lepidic was higher than that in the acinar and papillary (P<0.05), but the mutation rate of 19 exon in the papillary was higher than that in the lepidic (P<0.05). There was no significant difference of 19 and 21 exon in the acinar and papillary. Among 114 cases of lung adenocarcinoma in the biopsy specimen, the most percentage was the acinar (48.25%), the lepidic was secondly, and the papillary, micropapillary and solid adenocarcinoma was the minimal. The exon mutation of 19 and 21 exon alone was most common, while no obvious difference of 19 and 21 exon was found in different pathology classifications (P>0.05). CONCLUSIONS:The mutation rate of EGFR of lung adenocarcinoma in surgical resected specimen and biopsy specimen was not found difference, which was related to sex, and the female was predominant. The mutation rate of surgical specimen was higher in the young, while that of biopsy specimen was not related to the age. Apparent difference of the pathology type proportion was found in the two groups. The mutation of 19 and 21 exon alone was most common. The mutation of EGFR in surgical specimens was related to pathology types. The percentage of the lepidic adenocarcinoma was highest in the mutation of 21 exon alone. Among the mutation of 19 exon alone, the papillary was predominant. There was no obvious relationship between the mutation of 19 and 21 exon alone and pathology type in biopsy sample.

Distal‐type bronchiolar adenoma of the lung harboring an EGFR exon 21 p.L858R mutation: A case report

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Pulmonary Tumor with Notochordal Differentiation: a Case Report and Morphologic, Immunohistochemical and Molecular Study of Benign Notochordal Cell Tumor Originating in the Lung

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Coexistence of Low-Grade Fetal Adenocarcinoma and Adenocarcinoma in Situ of the Lung Harboring Different Genetic Mutations: A Case Report and Review of Literature

Epidermal Growth Factor Receptor Mutation P.a864v in Small Cell Lung Cancer and Lung Squamous Cell Carcinoma: a Case Report and Review of Literature

Frequent EGFR Exon 20 Insertion in the So‐called Peripheral‐type Squamous Cell Neoplasm of Uncertain Malignant Potential: a Variant of Bronchiolar Adenoma or Under‐recognised Entity?

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

[Relationship Between EGFR Mutations and Pathological Classification and Specimen of Lung Adenocarcinoma].

Case report: A case report and literature review about Pathological transformation of lung adenosquamous cell carcinoma

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

An exon 19 mutation of EGFR gene in the serum circulating DNA from patients with advanced lung cancer

Mutational analysis of exons 19 and 21 of the EGFR gene in lung adenocarcinoma

Successful EGFR Mutation Detection in Cytological Specimens of Lung Cancer with Challenging Biopsies by Integrating Virtual Bronchoscopy Navigation and Endobronchial Ultrasound Guidance with Highly Sensitive Next-Generation Sequencing: A Case Report

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma

Lung Adenocarcinoma with Concurrent ALK and ROS1 Rearrangement: A Case Report and Review of the Literatures

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma

Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.